<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00961766</url>
  </required_header>
  <id_info>
    <org_study_id>103NS101</org_study_id>
    <nct_id>NCT00961766</nct_id>
  </id_info>
  <brief_title>Evaluate the Safety, Tolerability and Pharmacokinetics of BG00010 (Neublastin) Administered to Sciatica Participants</brief_title>
  <official_title>Phase 1: A Single-Center, Randomized, Blinded, Placebo-Controlled, Single-Administration, Sequential-Cohort, Dose-Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BG00010 (Neublastin) Administered to Sciatica Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biogen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biogen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to determine the safety/tolerability profile, systemic
      PK behavior, and immunogenicity of single IV and SC administrations of BG00010 to sciatica
      participants.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2009</start_date>
  <completion_date type="Actual">February 2012</completion_date>
  <primary_completion_date type="Actual">February 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants experiencing Adverse Events (AEs)</measure>
    <time_frame>Up to 56 days post dosing</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Likert numerical pain rating scale</measure>
    <time_frame>Up to 56 days post dosing</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Quantitative Sensory Test (QST)</measure>
    <time_frame>Up to 28 days post dosing</time_frame>
    <description>QST; Vibratory, Cool Thermal,</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Intra Epidermal Nerve Fiber Density (IENFD)</measure>
    <time_frame>Up to 28 days post dosing</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum observed serum concentration (Cmax)</measure>
    <time_frame>Up to 5 days post dosing</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the serum concentration curve (AUC)</measure>
    <time_frame>Up to 5 days post dosing</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal half-life (t1/2)</measure>
    <time_frame>Up to 5 days post dosing</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Total body clearance (CL)</measure>
    <time_frame>Up to 5 days post dosing</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Steady state volume of distribution (Vss)</measure>
    <time_frame>Up to 5 days post dosing</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Sciatica</condition>
  <arm_group>
    <arm_group_label>BG00010 (Neublastin)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants may be randomized to escalating doses of BG00010 or matching placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants may be randomized to escalating doses of BG00010 or matching placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BG00010 (Neublastin)</intervention_name>
    <description>Single dose, weight-based IV administration</description>
    <arm_group_label>BG00010 (Neublastin)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Single dose IV matched placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Must have a diagnosis of unilateral sciatica, determined by the Investigator. Sciatica
             symptoms must be present for 6 or more weeks prior to the Screening Visit.

          -  Must have a body mass index (BMI) between 18 kg/m2 and 32 kg/m2.

          -  Must rate their pain at &gt;40 mm on the 100 mm Visual Analog Scale (VAS) of the
             Short-Form McGill Pain Questionnaire (SF-MPQ)at the Screening and Baseline Visits.

        Key Exclusion Criteria:

          -  History of malignancy or clinically significant (as determined by the Investigator)
             allergies, cardiac, endocrinologic, hematologic, hepatic, immunologic, metabolic,
             urologic, pulmonary, neurologic (not related to sciatica), dermatologic,
             rheumatic/joint, psychiatric, renal, and/or other major disease.

          -  History of signs or symptoms of peripheral neuropathy, other than symptoms of
             sciatica.

          -  History of severe allergic or anaphylactic drug-related reactions. NOTE: Other
             protocol defined Inclusion/Exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Biogen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 17, 2009</study_first_submitted>
  <study_first_submitted_qc>August 18, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 19, 2009</study_first_posted>
  <last_update_submitted>October 24, 2014</last_update_submitted>
  <last_update_submitted_qc>October 24, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 28, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sciatica</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

